##gff-version 3
##sequence-region Q13509 1 450
Q13509	UniProtKB	Chain	1	450	.	.	.	ID=PRO_0000048250;Note=Tubulin beta-3 chain	
Q13509	UniProtKB	Nucleotide binding	140	146	.	.	.	Note=GTP;Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q13509	UniProtKB	Modified residue	172	172	.	.	.	Note=Phosphoserine%3B by CDK1;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:16371510;Dbxref=PMID:16371510	
Q13509	UniProtKB	Modified residue	438	438	.	.	.	Note=5-glutamyl polyglutamate;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q2T9S0	
Q13509	UniProtKB	Modified residue	444	444	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q2T9S0	
Q13509	UniProtKB	Alternative sequence	1	72	.	.	.	ID=VSP_054659;Note=In isoform 2. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:14702039;Dbxref=PMID:14702039	
Q13509	UniProtKB	Natural variant	62	62	.	.	.	ID=VAR_062758;Note=In CFEOM3A%3B affects heterodimers formation%3B results in increased stability and reduced dynamics of microtubules. R->Q;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20074521;Dbxref=dbSNP:rs864321714,PMID:20074521	
Q13509	UniProtKB	Natural variant	178	178	.	.	.	ID=VAR_066206;Note=In CDCBM1%3B can form tubulin heterodimers that are properly incorporated into microtubules%3B the microtubules are less stable than wild-type. T->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20829227;Dbxref=dbSNP:rs747480526,PMID:20829227	
Q13509	UniProtKB	Natural variant	205	205	.	.	.	ID=VAR_066207;Note=In CDCBM1%3B does not form tubulin heterodimers%3B patient fibroblasts show no major alterations in the microtubule network%2C but the microtubules are less stable than wild-type. E->K;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20829227;Dbxref=dbSNP:rs878853257,PMID:20829227	
Q13509	UniProtKB	Natural variant	262	262	.	.	.	ID=VAR_062759;Note=In CFEOM3A%3B affects heterodimers formation%3B affects microtubules polymerization and depolymerization rates. R->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20074521;Dbxref=dbSNP:rs267607162,PMID:20074521	
Q13509	UniProtKB	Natural variant	262	262	.	.	.	ID=VAR_062760;Note=In CFEOM3A%3B severe phenotype with congenital facial weakness%2C congenital wrist and finger contractures%3B affects microtubules polymerization and depolymerization rates. R->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20074521;Dbxref=dbSNP:rs864321716,PMID:20074521	
Q13509	UniProtKB	Natural variant	302	302	.	.	.	ID=VAR_062761;Note=In CFEOM3A%3B affects heterodimers formation%3B results in increased stability and reduced dynamics of microtubules. A->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20074521;Dbxref=dbSNP:rs267607163,PMID:20074521	
Q13509	UniProtKB	Natural variant	302	302	.	.	.	ID=VAR_066208;Note=In CDCBM1%3B does not form tubulin heterodimers. A->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20829227;Dbxref=dbSNP:rs878853258,PMID:20829227	
Q13509	UniProtKB	Natural variant	323	323	.	.	.	ID=VAR_066209;Note=In CDCBM1%3B reduced heterodimers formation. M->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20829227;Dbxref=dbSNP:rs878853256,PMID:20829227	
Q13509	UniProtKB	Natural variant	380	380	.	.	.	ID=VAR_062762;Note=In CFEOM3A%3B affects heterodimers formation%3B results in increased stability and reduced dynamics of microtubules. R->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20074521;Dbxref=dbSNP:rs864321717,PMID:20074521	
Q13509	UniProtKB	Natural variant	410	410	.	.	.	ID=VAR_062763;Note=In CFEOM3A%3B severe phenotype with congenital facial weakness%3B lower extremity weakness and sensory loss in the second to third decade of life in one patient%3B affects microtubules polymerization and depolymerization rates. E->K;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20074521;Dbxref=dbSNP:rs267607165,PMID:20074521	
Q13509	UniProtKB	Natural variant	417	417	.	.	.	ID=VAR_062764;Note=In CFEOM3A%3B severe phenotype with congenital facial weakness%2C congenital wrist and finger contractures. D->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20074521;Dbxref=dbSNP:rs267607164,PMID:20074521	
Q13509	UniProtKB	Natural variant	417	417	.	.	.	ID=VAR_062765;Note=In CFEOM3A%3B some patients with lower extremity weakness and sensory loss in the second to third decade of life%3B also found in patients without CFEOM3A who developed polyneuropathy. D->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20074521;Dbxref=dbSNP:rs267607164,PMID:20074521	
Q13509	UniProtKB	Sequence conflict	275	275	.	.	.	Note=A->R;Ontology_term=ECO:0000305;evidence=ECO:0000305	
